Korean J Gastroenterol.  2024 Jun;83(6):253-255. 10.4166/kjg.2024.048.

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

• Hong H
• Choi J

• KMID: 2557113
• DOI: http://doi.org/10.4166/kjg.2024.048

Reference

1. Rinella ME, Lazarus JV, Ratziu V, et al. 2023; A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 78:1966–1986. DOI: 10.1097/HEP.0000000000000520. PMID: 37363821. PMCID: PMC10653297.

2. Sanyal AJ, Van Natta ML, Clark J, et al. 2021; Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 385:1559–1569. DOI: 10.1056/NEJMoa2029349. PMID: 34670043. PMCID: PMC8881985.

3. Harrison SA, Bedossa P, Guy CD, et al. 2024; A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 390:497–509. DOI: 10.1056/NEJMoa2309000. PMID: 38324483.

4. Kelly MJ, Pietranico-Cole S, Larigan JD, et al. 2014; Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 57:3912–3923. DOI: 10.1021/jm4019299. PMID: 24712661.

5. Harrison SA, Ratziu V, Anstee QM, et al. 2024; Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 59:51–63. DOI: 10.1111/apt.17734. PMID: 37786277.